THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
31 May 2022
Nuformix plc
("Nuformix" or the "Company")
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that Dr Alastair Riddell, the Company's Executive Chairman, has resigned from the Company with immediate effect in order to take up a full-time executive role with another company.
The Board will review the management requirements for the business whilst it continues to be supported through out-sourced operations.
Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: "Whilst it is disappointing that Alastair is leaving the Company, we thank him for his contribution to the Company over the past year and wish him well in his new position. The management requirements for the business will be considered and further updates provided in due course."
Enquiries:
| Nuformix plc |
|
| Dr Julian Gilbert, Non-executive Director Maddy Kennedy, Non-executive Director
| Via IFC Advisory
|
| Stanford Capital Partners Limited |
|
| Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
| John Howes (Corporate Broking) | +44 (0) 20 3650 3652
|
| IFC Advisory Limited |
|
| Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.